Literature DB >> 27631392

Exploring the HYDRAtion method for loading siRNA on liposomes: the interplay between stability and biological activity in human undiluted ascites fluid.

George R Dakwar1, Kevin Braeckmans1,2, Wim Ceelen3, Stefaan C De Smedt4, Katrien Remaut5.   

Abstract

Delivery of small interfering RNA (siRNA) is recently gaining tremendous attention for the treatment of ovarian cancer. The present study investigated the potential of different liposomal formulations composed of (2,3-dioleoyloxy-propyl)-trimethylammonium (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) encapsulating siRNA (hydration method) for their ability to knockdown luciferase (Luc) activity in human ovarian cancer SKOV-3 cells. Fluorescence single particle tracking (fSPT) and fluorescence correlation spectroscopy (FCS) in human-undiluted ascites fluid obtained from a peritoneal carcinomatosis patient revealed that cationic hydra-lipoplexes (HYDRA-LPXs) and HYDRA-LPXs decorated with stable DSPE-PEG (DSPE HYDRA-LPXs) showed high stability during at least 24 h. HYDRA-LPXs decorated with sheddable C8 and C16 PEG-Ceramides (Cer HYDRA-LPXs) resulted in rapid and premature release of siRNA already in the first hours. Despite their role in preventing aggregation in vivo, liposomes decorated with stable PEG residues resulted in a poor transfection compared to the ones decorated with sheddable PEG residues in reduced serum conditions. Yet, the transfection efficiency of both Cer HYDRA-LPXs significantly decreased following 1 h of incubation in ascites fluid due to a drastic drop in the cellular uptake, while DSPE HYDRA-LPXs are still taken up by cells, but too stable to induce efficient gene silencing.

Entities:  

Keywords:  Ascites; Peritoneal metastasis; Sheddable PEG; siRNA delivery; siRNA encapsulation

Mesh:

Substances:

Year:  2017        PMID: 27631392     DOI: 10.1007/s13346-016-0329-4

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  39 in total

1.  Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting.

Authors:  Shyh-Dar Li; Leaf Huang
Journal:  J Control Release       Date:  2010-03-23       Impact factor: 9.776

2.  Formation and intracellular trafficking of lipoplexes and polyplexes.

Authors:  Abdelatif Elouahabi; Jean-Marie Ruysschaert
Journal:  Mol Ther       Date:  2005-03       Impact factor: 11.454

3.  Disregarded Effect of Biological Fluids in siRNA Delivery: Human Ascites Fluid Severely Restricts Cellular Uptake of Nanoparticles.

Authors:  George R Dakwar; Kevin Braeckmans; Joseph Demeester; Wim Ceelen; Stefaan C De Smedt; Katrien Remaut
Journal:  ACS Appl Mater Interfaces       Date:  2015-10-27       Impact factor: 9.229

4.  Lipid nanoparticle delivery systems for siRNA-based therapeutics.

Authors:  C Wan; T M Allen; P R Cullis
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

5.  Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.

Authors:  Adam Judge; Kevin McClintock; Janet R Phelps; Ian Maclachlan
Journal:  Mol Ther       Date:  2005-11-07       Impact factor: 11.454

6.  Stabilized plasmid-lipid particles: construction and characterization.

Authors:  J J Wheeler; L Palmer; M Ossanlou; I MacLachlan; R W Graham; Y P Zhang; M J Hope; P Scherrer; P R Cullis
Journal:  Gene Ther       Date:  1999-02       Impact factor: 5.250

7.  An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels.

Authors:  Payam Zahedi; James Stewart; Raquel De Souza; Micheline Piquette-Miller; Christine Allen
Journal:  J Control Release       Date:  2011-11-26       Impact factor: 9.776

8.  Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression.

Authors:  E Ambegia; S Ansell; P Cullis; J Heyes; L Palmer; I MacLachlan
Journal:  Biochim Biophys Acta       Date:  2005-02-24

9.  PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles.

Authors:  Swaroop Mishra; Paul Webster; Mark E Davis
Journal:  Eur J Cell Biol       Date:  2004-04       Impact factor: 4.492

Review 10.  Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis - Mission possible?

Authors:  George R Dakwar; Molood Shariati; Wouter Willaert; Wim Ceelen; Stefaan C De Smedt; Katrien Remaut
Journal:  Adv Drug Deliv Rev       Date:  2016-07-13       Impact factor: 15.470

View more
  4 in total

1.  Optimal combination of cationic lipid and phospholipid in cationic liposomes for gene knockdown in breast cancer cells and mouse lung using siRNA lipoplexes.

Authors:  Yoshiyuki Hattori; Min Tang; Satomi Torii; Kana Tomita; Ayane Sagawa; Nodoka Inoue; Reo Yamagishi; Kei-Ichi Ozaki
Journal:  Mol Med Rep       Date:  2022-06-10       Impact factor: 3.423

2.  Difatty Acyl-Conjugated Linear and Cyclic Peptides for siRNA Delivery.

Authors:  Hung Do; Meenakshi Sharma; Naglaa Salem El-Sayed; Parvin Mahdipoor; Emira Bousoik; Keykavous Parang; Hamidreza Montazeri Aliabadi
Journal:  ACS Omega       Date:  2017-10-19

3.  Nanocarrier Lipid Composition Modulates the Impact of Pulmonary Surfactant Protein B (SP-B) on Cellular Delivery of siRNA.

Authors:  Roberta Guagliardo; Pieterjan Merckx; Agata Zamborlin; Lynn De Backer; Mercedes Echaide; Jesus Pérez-Gil; Stefaan C De Smedt; Koen Raemdonck
Journal:  Pharmaceutics       Date:  2019-08-23       Impact factor: 6.321

4.  Lipoplexes to Deliver Oligonucleotides in Gram-Positive and Gram-Negative Bacteria: Towards Treatment of Blood Infections.

Authors:  Sara Pereira; Rita Sobral Santos; Luís Moreira; Nuno Guimarães; Mariana Gomes; Heyang Zhang; Katrien Remaut; Kevin Braeckmans; Stefaan De Smedt; Nuno Filipe Azevedo
Journal:  Pharmaceutics       Date:  2021-06-29       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.